Friday, 25. 12. 2021          

Cancer Cell Research (Online ISSN: 2161-2609)

Current Issue

Vol.10  No.37

Article: The effect of transversus abdominis plane block combined with PCIA of different doses of butorphanol on postoperative analgesia after cesarean delivery : a double blind randomized controlled trial
by Pengpeng Wang, Qian Liu, Hongguang Song, Yonggang Xie
Cancer Cell Research 2022 9(36) 886-890; published online  28 February 2023
Abstract: Background: To investigate efficacy and safety of ropivacaine transversus abdominis plane (TAP) block combined with patient-controlled intravenous analgesia (PCIA) of different doses of butorphanol for postsurgical analgesia after cesarean delivery (CD).
Methods: Women with term pregnancy of 37 to 42 weeks scheduled for elective CD under general anesthesia. Patients were randomized 1:1:1:1 to ropivacaine 75 mg TAP block alone (T group), ropivacaine 75 mg TAP plus butorphanol 6mg PCIA (TB1 group), ropivacaine 75 mg TAP plus butorphanol 8mg PCIA (TB2 group) and ropivacaine 75 mg TAP plus butorphanol 10mg PCIA (TB3 group). The primary outcomes were postoperative uterine contraction pain, incision pain under the resting state and the moving state, number of PCA compression and observer’s assessment alert/sedation (OAA/S) scores; the secondary outcomes were incidence of postoperative drowsiness, dizziness, nausea and vomiting. The study was approved by the Ethics Committee of Yantai Yuhuangding Hospital. All participants provided their informed consent.
Results: At postoperative 30min, 2h, 4h, 24h and 48h timepoints, there was no significant difference on VAS scores of incision pain between the T group and TB1 group (p> 0.05). VAS scores of TB2 and TB3 groups were higher than T group (p<0.05). Compared with TB1 group, number of PCA compression was significantly more than the TB2 and TB3 groups (p<0.05) and no statistic difference was found between TB2 and TB3 groups (p> 0.05). The incidence of OAA/S scores less than 5 was higher in TB3 group than T, TB1 and TB2 groups at postoperative 4h, 24h and 48h (p<0.05). Incidence of postoperative drowsiness, dizziness, nausea and vomiting was higher in the TB3 group than T, TB1 and TB2 groups (p<0.05). And there was no statistic difference between T, TB1 and TB2 groups on postoperative complications.
Conclusion: TAP combined with butorphanol-PCIA was an effective postoperative analgesic strategy for cesarean delivery. As the sufficient analgesia intensity and the lower postoperative complications, butorphanol 8mg in PCIA is the most appropriate dose.

Open Access Download (free) PDF

Article: Research Progress of TMB in Predicting Prognosis and Efficacy of Lung Cancer
by Bo Wei, Yongping Mu
Cancer Cell Research 2022 9(36) 891-896; published online  28 February 2023
Abstract:Immune checkpoint inhibitors (ICIs) have changed therapeutic paradigms for patients across multiple cancer types and play an important role. However, due to the complexity and individual differences in immunotherapy, not all patients benefit from immunotherapy. New insights into the role of tumor mutational burden (TMB) suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options. In this paper, we will review TMB as a biomarker for immunotherapy, assess the efficacy of immunotherapy, present several combinations of biomarkers to improve treatment prediction, and further evaluate the limitations of TMB as a biomarker of immunotherapy for lung cancer.
KEYWORDS: Immune Checkpoint Inhibitor, Tumor Mutational Burden, Biomarkers

Open Access Download (free) PDF

Article: Advances in glioma ecDNA research
by Zhongyou Que, Sheng Liu, Bingxi Lei
Cancer Cell Research 2023 9(36) 897-902; published online  25 March 2023
Abstract:Glioma is the most common primary tumor of the central nervous system and the tumor genetics of glioma has been a hot topic. In recent years, the role of ecDNA in tumors, especially glioma, has been gradually recognized. ecDNA can accelerate tumor evolution and mediate glioma drug resistance activity by randomly distributing in the interphase due to the lack of mitotic structure. The circle structure of ecDNA also has the characteristics of high openness, strong transcriptional activity and diverse regulatory modes. The study of glioma ecDNA has gone through three stages: classical karyotype analysis, basic function study and regulatory molecular mechanism study. In the era of karyotype analysis, early studies focused mostly on the description of cell karyotypes, but later merged with research on oncogenes. In the era of functional study of ecDNA, not only have many oncogenes located on ecDNA had been discovered, but also the mechanism of ecDNA involvement in glioma drug resistance had been revealed. In the past five years, the finer molecular regulatory mechanisms have become essential in further revealing the unique functions of ecDNA, mainly due to the advancement of biology experiments research tools and bioinformatics technologies.

Open Access Download (free) PDF